COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN

LATIN AMERICA?

Nicola Bedlington Secretary General European Patients' Forum

Glasgow, 6/11/2017 ISPOR 20th Annual European Congress

A STRONG PATIENTS' VOICE TO DRIVE BETTER HEALTH IN EUROPE



@eupatientsforum

About EPF

- European Patients' Forum
 - Independent & non-governmental
 - Umbrella organisation
 - Active since 2003
 - EU patients' voice
- Our members
 - 74 patient Umbrella groups
 - EU disease specific organisations &
 - National patient coalitions
- Our vision
 - All patients with chronic conditions in Europe have **equal** access to **high quality**, **patient-centred** health and related care

55 A STRONG PATIENTS' VOICE TO DRIVE BETTER HEALTH IN EUROPE 35



FPF

EUPATI: an innovative training model

PF Patients

An unprecedented collaboration: Patient organisations, academia, health NGOs, pharmaceutical industry


- <u>IMI-EUPATI</u>: Funded by IMI (PPP between EC and EFPIA), ran for 5 years from Feb 2012 – Jan 2017, Consortium of 30 + members led by EPF
- <u>EUPATI as current EPF programme</u>: continuation of Patient Expert Course, along with support for ENPs and expansion of IT and capacity building tools for patients

EUPATI develops and disseminates objective, credible, correct and upto-date information on medicines R&D in 8 European languages (3 more on the way!)

EUPATI helps build competencies and capacity among patients and public to get involved **EUPATI facilitates patient involvement** in R&D to support academia, industry, authorities and ethics committees.

European Patients' Academy

on Therapeutic Innovation



EUPATI Fellows has created influencers and leaders



Source: The EUPATI Fellow Experience Poll, December 2016, 52 respondents (83 fellows)		European Patients' Academy on Therapeutic Innovation		
Role	Before Course	EUPATI	Post Course	
Member of patient organisation, not actively involved	17%	-	2%	
Active role in a patient organisation	62%		71%	
Leadership role in a patient organisation	62%		71%	
Employee of a patient organisation	25%	-	23%	
Volunteer role in a patient organisation	60%	-	67%	
Presenting at conferences, workshops etc.	63%	-	83%	
Advising a pharmaceutical company	13%		44%	
Advising a regulatory agency	21%	-	42%	
Advising a reimbursement agency	4%		8%	

55 A STRONG PATIENTS' VOICE TO DRIVE BETTER HEALTH IN EUROPE 33

18+ EUPATI National Platforms

EUPATI National Platforms

- bring all stakeholders together in respective countries
- address educational needs in R&D
- disseminate EUPATI's training material to patient organisations

National platforms set up in AT, FR, DE, IE, IT, LU, MT, PL, ES, CH, UK, DK, SK, PT

Additional platform initiatives ongoing in BE, NO, GR, RO, SRB





FPF

EUPAT



EUPATI Guidances supports patient interaction in R&D and regulatory affairs **FP**

Following an extensive consultation of the community, EUPATI has developed guidance for the interaction of patient organisations:

- in industry-led R&D
- with HTA bodies
- in regulatory processes
- in ethics committees


See EUPATI.eu > Resources > Guidances or <u>http://eupati.eu/guidances</u>

Webinar series – recordings available https://www.eupati.eu/category/webinar/



EUPATI

66 A STRONG PATIENTS' VOICE TO DRIVE BETTER HEALTH IN EUROPE 33



Patient Access Partnership - PACT




- Patient Access Partnership (PACT) is a patient-led multi-stakeholder network of which EPF was a founding member
- Other members: policy-makers, academia, industry, public health organisations, health care professionals





66 A STRONG PATIENTS' VOICE TO DRIVE BETTER HEALTH IN EUROPE 35



Conclusions



- New climate of cooperation and trust between industry/patients, and among the health stakeholder community
- Essential to address access and wider societal challenges
- These relationships not 'comfortable' but dynamic, challenging, ambitious, solutionoriented
- Precious, new and potentially fragile must be underpinned by highest level of integrity and ethics
- External perceptions key- vigilance and rigor



66 A STRONG PATIENTS' VOICE TO DRIVE BETTER HEALTH IN EUROPE 35

Conclusions 2

- We need to **maximise value** of dialogue and collaboration
- Patient Engagement in the entire innovation chain or life cycle a must
- This requires **patient education and training** on therapeutic innovation
- It also requires a 'full circle' approach and capacity building at national level
- And an enabling policy environment







